Abstract:
본 발명은 천식 동물 모델의 폐와 BALF(bronchoalveolar lavage fluid)에서 발현이 유도되는 신규한 단백질인 Ym2 단백질의 이소자임(isozyme)인 Ym2-1 및 이의 용도에 관한 것이다. 본 발명의 Ym2-1은 키티나제 과(chitinase family)에 속하며, Ym 단백질의 일종으로 천식동물 모델의 폐에서 강하게 발현되는 단백질로, Ym2-1의 서열을 확인하여 재조합 단백질을 만든 후 세포에 자극시켜 확인한 결과 COX-2 단백질의 발현유도, PGE2 생산 증가, iNOS 단백질 발현 유도 및 NO 생산 증가의 기능을 갖고 있음을 확인하였다. 따라서 본 발명은 Ym2 단백질의 이소자임인 Ym2-1이 관여하는 생리현상의 연구 분야 및 관련된 질환의 진단, 예방 및 치료에 유용하게 사용될 수 있다. 키티나제, Ym2 이소자임(isozyme), 재조합 단백질, 천식, COX-2, PGE2, iNOS, NO, PCR
Abstract:
A composition for the prevention or treatment of inflammation and allergic disease comprising the extract of Aralia cordata Thunb is provided to reduce side effects of the prevention or treatment, and to inhibit 5-lipoxygenase dependent production of leukotriene C4 which participates in allergy and inflammation responses. The composition for the prevention or treatment of inflammation and allergic disease comprises the extract of Aralia cordata Thunb as an effective ingredient, wherein the Aralia cordata Thunb extract is obtained by extracting Aralia cordata Thunb with a solvent selected from water, methanol and ethanol; the composition treats an animal model having inflammation induced by croton oil and phorbol myristate acetate; the amount of Aralia cordata Thunb extract is 0.01-50% based on the total weight of the composition; and the inflammation and allergic diseases are acute or chronic inflammation disease, bronchial asthma, allergic rhinitis, allergic asthma or allergic dermatitis.
Abstract:
A composition for the prevention or treatment of asthma and allergic disease comprising the extract of Ailanthus altissima is provided to inhibit COX-2(cyclooxygenase-2) dependent PGD2(prostaglandin D2) production, and the production of eotaxin and IgE(immunoglobulin E). The composition for the prevention or treatment of asthma and allergic disease comprises the extract of Ailanthus altissima, wherein the Ailanthus altissima extract is prepared by extracting Ailanthus altissima with a solvent selected from water, methanol and ethanol; the asthma and allergic diseases include bronchial asthma, allergic rhinitis, allergic asthma and allergic dermatitis; the amount of Ailanthus altissima extract is 0.01-50% based on the total weight of the composition; the composition is a pharmaceutical or food composition; and the food composition is formulated as powder, granule, tablet, capsule or drink.
Abstract:
본 발명은 항염증 및 항알러지활성을 갖는 노루오줌( Astilbe rubra ) 추출물을 함유하는 조성물에 관한 것으로, 노루오줌 추출물로부터 분리한 아스틸빅산 (Astilbic acid, ACH53c) 또는 펠토보이키놀릭산(Peltoboykinolic acid) 유도체를 함유함으로써 각종 염증 질환의 원인이 되는 혈소판활성화인자(PAF, platelet activating factor)의 전구물질인 리소PAF(lysoPAF)로부터 PAF를 합성하는 효소인 리소PAF-아세틸트란스페라제(lysoPAF-acetyltransferase)의 활성을 저해하여 PAF의 생성을 억제하는 활성을 갖는 동시에, 리폭시게나제(5-LO, 5-lipoxygenase)의 활성을 저해하여 염증성 에이코사노이드(eicosanoid)의 생성을 방지함으로써 각종 염증 및 알러지성 질환의 예방 및 치료용 약학 조성물에 관한 것이다.
Abstract:
PURPOSE: Provided is a composition having anti-inflammatory or anti-allergic activity which comprises the extract of Astilbe rubra or astilbic acid and peltoboykinolic acid derivatives. Therefore, the composition inhibits the activity of lysoPAF-acetyltransferase which synthesizes PAF, and 5-lipoxygenase which synthesizes eicosanoid. CONSTITUTION: The pharmaceutical composition for preventing and treating inflammatory and atopic diseases is characterized by containing 0.01-50% of: the crude extract of Astilbe rubra using methanol or the nonpolar solvent soluble extrct of Astilbe rubra using hexan, as active ingredients; or astilbic acid and peltoboykinolic acid derivatives or their pharmaceutically acceptable salts.